Understanding immunogenicity is a key challenge in the development of therapeutics with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity. This conference explores the latest updates on the prediction and reduction of immunogenicity, clinical results and interpetations and optimising bioassays.
Led by selected case studies from leading drug developement teams, bioanalytical experts, and academics we aim to provide the insights and sharing necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.
- Day 1
- 8:30
- Registration & Coffee
- 9:00
- Chair's Opening Remarks
- Guilhem Richard, Computational Immunologist, EpiVax Inc
- 9:10
- How to switch off unwanted immune responses
- David Wraith, Chief Scientific Officer and Founder, Apitope International NV
- 9:50
- Synthetic Vaccine Particles (SVPs) for the prevention of anti-drug antibodies
- Kei Kishimoto , Chief Scientific Officer, Selecta Biosciences
- 10:30
- Morning Coffee
- 11:00
- Achieving immunological tolerance – are we there yet?
- Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
- 11:40
- Evaluation of the immunogenicity of orally administered recombinant human BSSL in a phase III clinical study in pre-term infants
- Margareta Wiken, Bioanalytical Manager, Swedish Orphan Biovitrum
- 12:20
- Networking Lunch
- 13:20
- Early immunogenicity assessment of biotherapeutics: a decade at a glance
- Sofie Pattijn, Chief Technology Officer, ImmunXperts
- 14:00
- Predicting T cell immunogenicity; Moving beyond MHC binding
- Morten Nielsen, Associate Professor, The Technical University Of Denmark
- 14:40
- Afternoon Tea
- 15:20
- Immune tolerant mice as the model for studying immunogenicity?
- Grzegorz Kijanka, Postdoctoral Researcher , Leiden Academic Centre for Drug Research, Leiden University
- 16:00
- Validation of cell based antibody neutralisation assays
- Bassam Hallis, Head of Pre-Clinical Development, Public Health England
- 16:40
- Mission Impossible? Tweaking Bridging ELISA to Achieve Required Drug Tolerance for ADA Detection of Therapeutic Antibodies
- Linglong Zou, Director of Experimental Immunology, Teva Pharmaceuticals
- 17:20
- Chair’s Closing Remarks and Close of Day One
- Guilhem Richard, Computational Immunologist, EpiVax Inc
- Day 2
- 8:30
- Registration & Coffee
- 9:00
- Chair's Opening Remarks
- Sandra Garces, Rheumatologist Consultant and Researcher , Garcia de Orta’s Hospital
- 9:10
- Predicting Immunogenicity in the Era of Personalized Medicine: A Need for Individual Risk Assessment
- Guilhem Richard, Computational Immunologist, EpiVax Inc
- 9:50
- Drug Immunogenicity: What have we learned from the use of biologics in clinical practice?
- Sandra Garces, Rheumatologist Consultant and Researcher , Garcia de Orta’s Hospital
- 10:30
- Morning Coffee
- 11:00
- RG7787 - The coming of age of immunotoxins for solid tumour therapy. Are we there yet?
- Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development , Roche Innovation Center Penzberg
- 11:40
- Immunogenicity prediction and assessment of nanobodies
- Chloe Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels
- 12:20
- Networking Lunch
- 13:20
- Peptide immunotherapy for the treatment of autoimmune disease – closer to a cure?
- Emma Smith, Senior Group Leader, UCB
- 14:00
- ABIRISK: using immunological signatures to predict immunogenicity
- Marsilio Adriani, Postdoctoral Research Associate, University College London
- 14:40
- Afternoon Tea
- 15:20
- The two main outcomes of T cell amplification assays for immunogenicity prediction: T cell repertoire and epitopes
- Bernard Maillere, Research Director and Head, Immunology Laboratory, Institute of Biology and Technologies
- 16:00
- An integrated approach to managing immunogenicity risk and drug immune modulation
- Jeremy Fry, Assay Specialist , ProImmune Ltd.
- 16:40
- Chair's Closing Remarks and Close of Day Two
- Sandra Garces, Rheumatologist Consultant and Researcher , Garcia de Orta’s Hospital
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook